{"product_id":"tirzepatide-120mg","title":"TIRZEPATIDE 120mg","description":"\u003cp\u003eTirzepatide is a 39–amino acid dual incretin receptor agonist that activates both GLP‑1 and GIP receptors, enhancing glucose‑dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite\u003csup\u003e\u003ca href=\"https:\/\/peptidedosages.com\/single-peptide-dosages\/tirzepatide-30mg-vial-dosage-protocol\/#ref-1\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e\u003csup\u003e\u003ca href=\"https:\/\/peptidedosages.com\/single-peptide-dosages\/tirzepatide-30mg-vial-dosage-protocol\/#ref-2\"\u003e[2]\u003c\/a\u003e\u003c\/sup\u003e. Its ~5‑day half‑life allows convenient\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003eonce‑weekly subcutaneous\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003edosing\u003csup\u003e\u003ca href=\"https:\/\/peptidedosages.com\/single-peptide-dosages\/tirzepatide-30mg-vial-dosage-protocol\/#ref-1\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e. Clinical trials demonstrate superior glycemic control and weight reduction compared to selective GLP‑1 agonists\u003csup\u003e\u003ca href=\"https:\/\/peptidedosages.com\/single-peptide-dosages\/tirzepatide-30mg-vial-dosage-protocol\/#ref-3\"\u003e[3]\u003c\/a\u003e\u003c\/sup\u003e\u003csup\u003e\u003ca href=\"https:\/\/peptidedosages.com\/single-peptide-dosages\/tirzepatide-30mg-vial-dosage-protocol\/#ref-4\"\u003e[4]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eReconstitute:\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eAdd\u003cspan\u003e \u003cstrong\u003e5\u003c\/strong\u003e\u003c\/span\u003e\u003cstrong\u003e.0 mL\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003ebacteriostatic water →\u003cstrong\u003e 120.0 mg\/mL\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003econcentration.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTypical weekly range:\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003e2.5–15 mg\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eonce weekly (gradual 4‑week titration steps).\u003c\/li\u003e\n\u003cli\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eEasy measuring:\u003c\/strong\u003e At \u003cstrong\u003e24 mg\/mL\u003c\/strong\u003e, \u003cstrong\u003e1 unit = 0.01 mL = 0.24 mg = 240 mcg\u003c\/strong\u003e on a U-100 insulin syringe.\u003cspan class=\"PDq2pG_selectionAnchor\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Lyophilized: freeze at \u003cstrong\u003e−20 °C (−4 °F)\u003c\/strong\u003e; after reconstitution, refrigerate at \u003cstrong\u003e2–8 °C (35.6–46.4 °F)\u003c\/strong\u003e; use within 28 days.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4\u003eStandard \/ Gradual Approach (5 mL = 24 mg\/mL)\u003c\/h4\u003e\n\u003cdiv class=\"group TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth class=\"last:pe-10\"\u003ePhase\u003c\/th\u003e\n\u003cth class=\"last:pe-10\"\u003eWeekly Dose\u003c\/th\u003e\n\u003cth class=\"last:pe-10\"\u003eUnits per Injection\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeeks 1–4\u003c\/td\u003e\n\u003ctd\u003e2.5 mg\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e10.4 units (0.104 mL) × 1 injection\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeeks 5–8\u003c\/td\u003e\n\u003ctd\u003e5 mg\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e20.8 units (0.208 mL) × 1 injection\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeeks 9–12\u003c\/td\u003e\n\u003ctd\u003e7.5 mg\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e31.25 units (0.313 mL) × 1 injection\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeeks 13–16\u003c\/td\u003e\n\u003ctd\u003e10 mg\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e41.7 units (0.417 mL) × 1 injection\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp\u003e\u003cstrong\u003eFrequency:\u003c\/strong\u003e Inject \u003cstrong\u003eonce weekly\u003c\/strong\u003e subcutaneously on the same day each week. Dose increases occur every 4 weeks to minimize gastrointestinal side effects. \u003cem\u003eHigher doses (12.5–15 mg\/week) may be used in subsequent phases if tolerated and clinically indicated.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 id=\"reconstitution-steps-3\"\u003eReconstitution Steps\u003c\/h3\u003e\n\u003col\u003e\n\u003cli\u003eDraw\u003cstrong\u003e 5.0 mL\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003ebacteriostatic water with a sterile syringe.\u003c\/li\u003e\n\u003cli\u003eInject slowly down the vial wall; avoid foaming.\u003c\/li\u003e\n\u003cli\u003eGently swirl\/roll until dissolved (do not shake).\u003c\/li\u003e\n\u003cli\u003eLabel with reconstitution date and refrigerate at\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003e2–8 °C (35.6–46.4 °F)\u003c\/strong\u003e, protected from light.\u003c\/li\u003e\n\u003cli\u003eUse within\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003e28 days\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eof reconstitution\u003csup\u003e\u003ca href=\"https:\/\/peptidedosages.com\/single-peptide-dosages\/tirzepatide-30mg-vial-dosage-protocol\/#ref-6\"\u003e[6]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/li\u003e\n\u003c\/ol\u003e","brand":"USA Peptides","offers":[{"title":"Default Title","offer_id":48810020929785,"sku":null,"price":0.0,"currency_code":"PYG","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0790\/5394\/7129\/files\/ChatGPT_Image_15_de_jan._de_2026_08_30_57.png?v=1768477650","url":"https:\/\/zenithlabsusa.com\/products\/tirzepatide-120mg","provider":"USA Peptides","version":"1.0","type":"link"}